At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 56 enrolled
Drug / intervention
Everolimus +1 moredrug
Likely dose
Everolimus 2.5mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Trial of Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in CD20+, B-cell Lymphomas, Gray Zone Lymphoma, and Hodgkin's Lymphoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins·interventional·Posted Aug 15, 2012·Updated Oct 26, 2021
In Brief
A Phase 2 clinical trial evaluating Everolimus and Rituximab for CD20+, B-cell Lymphomas and 5 related conditions. Completed, enrolled 56 participants across 1 site.
Detailed Summary
This research is being done to determine if combining an investigational drug called Everolimus with Rituximab can reduce the risk of your cancer from returning after high dose chemotherapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCD20+, B-cell Lymphomas, Mantle Cell Lymphoma, Non-Mantle Cell Low Grade B Cell Lymphomas (SLL/CLL), Transformed Lymphoma/DLBCL/PMBCL, Hodgkin's Disease, Gray Zone Lymphoma
CountriesUnited States
CollaboratorsNovartis Pharmaceuticals
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedAug 2012
Enrollment StartSep 2012
Primary CompletionOct 2017
Study CompletionAug 2020
TodayJul 2026
First PostedAug 15, 2012
Enrollment StartSep 1, 2012
Primary CompletionOct 1, 2017
Study CompletionAug 1, 2020
TodayJul 2, 2026
Enrollment to primary: 5.1 yearsPosted 13.9 years ago
Interventions
Everolimusdrug
The initial dose of everolimus will be 2.5mg orally daily for a total of one year to maintain a target trough concentration between 3-15 ng/mL.
Rituximabbiological
375mg/m2 day +1 and then every 90 days for 1 year (a total of 4 infusions)